Enanta Pharmaceuticals Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 74

Employees

  • Stock Symbol
  • ENTA

Stock Symbol

  • Share Price
  • $7.62
  • (As of Friday Closing)

Enanta Pharmaceuticals General Information

Description

Enanta Pharmaceuticals Inc is a biotechnology company that uses its robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs with an emphasis on viral infections and immunological diseases. The company has single operating segment.

Contact Information

Website
www.enanta.com
Formerly Known As
NovirX
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 4 Kingsbury Avenue
  • Watertown, MA 02472
  • United States
+1 (617)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 4 Kingsbury Avenue
  • Watertown, MA 02472
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enanta Pharmaceuticals Stock Performance

As of 20-Nov-2026, Enanta Pharmaceuticals’s stock price is $7.62. Its current market cap is $222M with 29.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.62 $7.98 $7.56 - $17.15 $222M 29.2M 289K -$2.35

Enanta Pharmaceuticals Financials Summary

As of 30-Sep-2026, Enanta Pharmaceuticals has a trailing 12-month revenue of $63M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Sep-2026 FY 2025 30-Sep-2025 FY 2024 30-Sep-2024
EV 251,334 251,334 111,183 41,419
Revenue 63,001 63,001 65,324 67,635
EBITDA (57,577) (57,577) (80,724) (119,282)
Net Income (68,248) (68,248) (81,889) (116,045)
Total Assets 275,577 275,577 280,732 376,652
Total Debt 54,757 54,757 57,903 55,467
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Enanta Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Enanta Pharmaceuticals‘s full profile, request access.

Request a free trial

Enanta Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Enanta Pharmaceuticals‘s full profile, request access.

Request a free trial

Enanta Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Enanta Pharmaceuticals Inc is a biotechnology company that uses its robust, chemistry-driven approach and drug discovery
Biotechnology
Watertown, MA
74 As of 2026

San Francisco, CA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Enanta Pharmaceuticals Competitors (84)

One of Enanta Pharmaceuticals’s 84 competitors is Pliant Therapeutics, a Formerly VC-backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pliant Therapeutics Formerly VC-backed San Francisco, CA
Vir Biotechnology Formerly VC-backed San Francisco, CA
Ayala Pharmaceuticals Corporation Wilmington, DE
Dynavax Technologies Formerly VC-backed Emeryville, CA
Lisata Therapeutics Corporation Basking Ridge, NJ
You’re viewing 5 of 84 competitors. Get the full list »

Enanta Pharmaceuticals Patents

Enanta Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026217507-A1 Anti-inflammatory compounds Pending 08-Apr-2025
WO-2026198843-A1 Anti-inflammatory compounds Pending 21-Mar-2025
WO-2026193124-A1 Anti-inflammatory compounds Pending 13-Mar-2025
WO-2026193125-A1 Anti-inflammatory compounds Pending 13-Mar-2025
WO-2026183251-A1 Anti-inflammatory compounds Pending 27-Feb-2025 C07D471/04
To view Enanta Pharmaceuticals’s complete patent history, request access »

Enanta Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enanta Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.23 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Enanta Pharmaceuticals’s complete esg history, request access »

Enanta Pharmaceuticals FAQs

  • When was Enanta Pharmaceuticals founded?

    Enanta Pharmaceuticals was founded in 1995.

  • Where is Enanta Pharmaceuticals headquartered?

    Enanta Pharmaceuticals is headquartered in Watertown, MA.

  • What is the size of Enanta Pharmaceuticals?

    Enanta Pharmaceuticals has 74 total employees.

  • What industry is Enanta Pharmaceuticals in?

    Enanta Pharmaceuticals’s primary industry is Biotechnology.

  • Is Enanta Pharmaceuticals a private or public company?

    Enanta Pharmaceuticals is a Public company.

  • What is Enanta Pharmaceuticals’s stock symbol?

    The ticker symbol for Enanta Pharmaceuticals is ENTA.

  • What is the current stock price of Enanta Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Enanta Pharmaceuticals is $7.62.

  • What is the current market cap of Enanta Pharmaceuticals?

    The current market capitalization of Enanta Pharmaceuticals is $222M.

  • What is Enanta Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Enanta Pharmaceuticals is $63M.

  • Who are Enanta Pharmaceuticals’s competitors?

    Pliant Therapeutics, Vir Biotechnology, Ayala Pharmaceuticals, Dynavax Technologies, and Lisata Therapeutics are some of the 84 competitors of Enanta Pharmaceuticals.

  • What is Enanta Pharmaceuticals’s annual earnings per share (EPS)?

    Enanta Pharmaceuticals’s EPS for 12 months was -$2.35.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process